Phase II Study for Combination of Camrelizumab and Apatinib in the Second-line Treatment of Recurrent or Metastatic Adrenocortical Carcinoma
Clinical trial NCT04318730 · UNKNOWN
Trial details
- NCT number
- NCT04318730
- Sponsor
- West China Hospital
- Status
- UNKNOWN
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2020-10-01
- Primary completion
- 2023-12-01
- Enrollment
- 21
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.